WNT3A and hepatocellular carcinoma: Notably, the incidence of serum Wnt3a was 81.4% in HCC patients with AFP level less than 20 μg/L (48/59), 92.6% in the cases with tumor size less than 3.0 cm (75/81), and up to 93.9% when Wnt3a plus AFP combination.